Kiora Pharmaceuticals Inc (KPRX) fair value: what the stock is really worth
As of Nov 20, 2026: fair value (intrinsic value) of Kiora Pharmaceuticals Inc stock $0.713, price $0.72, that is 1.0% below the price, quality 26 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently applies, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Kiora Pharmaceuticals Inc
KPRX · USRising price, but the stock is already about fairly priced and weak company: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 22, 2026.
How to read this chart
60‑month range $0.72 – $810.00 · fair‑value band $0.535 – $0.891 · the $0.72 price screens above the $0.713 fair value. As of Nov 22, 2026.
Every Wednesday you see whether Kiora Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases.
Show moreShow less
Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease.
The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis.
It has a strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301. The company operates in the United States, Austria, and Australia.
The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
Stock analysis
Kiora Pharmaceuticals Inc (KPRX) currently trades at $0.72, while our estimate is $0.713, so the stock looks roughly fairly valued today (gap 1.0%).
Show more
Valuation
None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $0.535 (bear) to $0.891 (bull), the price of $0.72 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Kiora Pharmaceuticals Inc reported revenue of $0 in FY2025 versus $12.1K in FY2021. Reported net income was −$10.8M in FY2025.
Key figures
Market cap $4.4M Micro · P/S ratio 3.19 · EPS (TTM) $-2.72 · Return on equity −67.7% · Return on assets (EBIT) −51.0% (5-year average) · Operating margin −890% · Revenue (TTM) $1.0M · Free cash flow −$10.1M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).
What moves the price
The share trades about 75% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −4% fair-value upside, at −1%, KPRX screens cheaper than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, no officer or director bought or sold shares on the open market.
Plus 2 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 20, 2026. All filings at the SEC ↗
Revenue & earnings trend
Watch KPRX, get fair value alerts →
Compare Kiora Pharmaceuticals Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 854 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Fair value gap by industry
- Return on assets by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $920.69 | $1,275.02 | +38% | vs KPRX |
| Vertex Pharmaceuticals Incorporated VRTX | $515.02 | $566.52 | +10% | vs KPRX |
| Samsung Biologics Co 207940 | ₩1,355,000 | ₩1,490,500 | +10% | vs KPRX |
| argenx SE ARGX | $925.70 | $908.40 | −2% | vs KPRX |
| CSL Limited CSL | A$197.29 | A$188.80 | −4% | vs KPRX |
| BeOne Medicines AG 6160 | HK$230.80 | HK$152.92 | −34% | vs KPRX |
| Moderna, Inc MRNA | $195.00 | $119.97 | −38% | vs KPRX |
| Revolution Medicines, Inc RVMD | $161.20 | $83.14 | −48% | vs KPRX |
| Celltrion, Inc 068270 | ₩213,000 | ₩74,574 | −65% | vs KPRX |
| Royalty Pharma plc RPRX | $68.45 | $19.01 | −72% | vs KPRX |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Kiora Pharmaceuticals Inc (KPRX) overvalued or undervalued?
What is the fair value of KPRX?
What is the quality score of KPRX?
What is the price target for Kiora Pharmaceuticals Inc (KPRX)?
What is the Kiora Pharmaceuticals Inc stock forecast for 2026?
What is the revenue of Kiora Pharmaceuticals Inc (KPRX)?
What is the intrinsic value of Kiora Pharmaceuticals Inc (KPRX)?
Is Kiora Pharmaceuticals Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of KPRX?
How much is Kiora Pharmaceuticals Inc worth?
What do the bullish and bearish scenarios say about KPRX?
How solid is the balance sheet of Kiora Pharmaceuticals Inc (KPRX)?
How far is KPRX from its 52-week high?
Which stocks are comparable to Kiora Pharmaceuticals Inc?
Is Kiora Pharmaceuticals Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Kiora Pharmaceuticals Inc (KPRX)?
What should I pay attention to with Kiora Pharmaceuticals Inc right now?
Key figures of Kiora Pharmaceuticals Inc
How large is the market capitalisation of Kiora Pharmaceuticals Inc (KPRX)?
What is the P/S ratio of Kiora Pharmaceuticals Inc (KPRX)?
What are the earnings per share of Kiora Pharmaceuticals Inc (KPRX)?
What is the return on equity of Kiora Pharmaceuticals Inc (KPRX)?
What is the EBIT return on assets of Kiora Pharmaceuticals Inc (KPRX)?
What is the operating margin of Kiora Pharmaceuticals Inc (KPRX)?
How much free cash flow does Kiora Pharmaceuticals Inc (KPRX) generate?
How much net cash does Kiora Pharmaceuticals Inc (KPRX) hold?
Watch Kiora Pharmaceuticals Inc in the live analysis
One click puts Kiora Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.